GR3007251T3 - - Google Patents

Info

Publication number
GR3007251T3
GR3007251T3 GR930400472T GR930400472T GR3007251T3 GR 3007251 T3 GR3007251 T3 GR 3007251T3 GR 930400472 T GR930400472 T GR 930400472T GR 930400472 T GR930400472 T GR 930400472T GR 3007251 T3 GR3007251 T3 GR 3007251T3
Authority
GR
Greece
Prior art keywords
hydrogen
4alkyl
medicament
chem
hydroxy
Prior art date
Application number
GR930400472T
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10617727&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GR3007251(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GR3007251T3 publication Critical patent/GR3007251T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GR930400472T 1987-05-21 1993-03-05 GR3007251T3 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878712073A GB8712073D0 (en) 1987-05-21 1987-05-21 Medicament

Publications (1)

Publication Number Publication Date
GR3007251T3 true GR3007251T3 (el) 1993-07-30

Family

ID=10617727

Family Applications (1)

Application Number Title Priority Date Filing Date
GR930400472T GR3007251T3 (el) 1987-05-21 1993-03-05

Country Status (21)

Country Link
US (2) US4824860A (el)
EP (1) EP0299602B1 (el)
JP (1) JPH062672B2 (el)
AT (1) ATE83659T1 (el)
AU (1) AU599792B2 (el)
CA (1) CA1305421C (el)
DE (1) DE3876877T2 (el)
DK (1) DK169609B1 (el)
ES (1) ES2052717T3 (el)
GB (1) GB8712073D0 (el)
GR (1) GR3007251T3 (el)
HK (1) HK1000913A1 (el)
HU (1) HU201871B (el)
IE (1) IE63511B1 (el)
LU (1) LU90098I2 (el)
MX (1) MX9203543A (el)
NL (1) NL970006I2 (el)
NZ (1) NZ224709A (el)
PH (1) PH23867A (el)
PT (1) PT87542B (el)
ZA (1) ZA883602B (el)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9008605D0 (en) * 1990-04-17 1990-06-13 Smith Kline French Lab Process
GB9015095D0 (en) * 1990-07-09 1990-08-29 Smith Kline French Lab Therapeutic method
JPH07506823A (ja) * 1992-05-18 1995-07-27 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 記憶障害，性的機能不全およびパーキンソン氏病の治療のためのインドロン誘導体の使用
GB9300309D0 (en) * 1993-01-08 1993-03-03 Smithkline Beecham Plc Process
GB9511366D0 (en) * 1995-06-06 1995-08-02 Smithkline Beecham Plc Novel formulations
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
GB9612752D0 (en) * 1996-06-19 1996-08-21 Smithkline Beecham Plc Novel treatment
ES2179362T3 (es) * 1996-08-27 2003-01-16 Wyeth Corp Derivados de 4-aminoetoxi indolona.
CA2327477A1 (en) * 1998-04-13 1999-10-21 James Albert Nelson 4-amino-(ethylamino)-oxindole dopamine autoreceptor agonists
US6176242B1 (en) 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6218421B1 (en) * 1999-07-01 2001-04-17 Smithkline Beecham P.L.C. Method of promoting smoking cessation
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US6277875B1 (en) * 2000-07-17 2001-08-21 Andrew J. Holman Use of dopamine D2/D3 receptor agonists to treat fibromyalgia
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
US6871098B2 (en) * 2000-10-30 2005-03-22 Medtronic, Inc. Method for treating obsessive-compulsive disorder with electrical stimulation of the brain internal capsule
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
US20060069039A1 (en) * 2002-09-17 2006-03-30 Alan Crossman Treatment of dyskinesia
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
WO2005051488A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Combination of dopamine agonists and monoamine reuptake inhibitors
DE10361258A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
US7378439B2 (en) * 2004-01-20 2008-05-27 Usv, Ltd. Process for the preparation of 4-(2-dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride
US20050197385A1 (en) * 2004-02-20 2005-09-08 Schwarz Pharma Ag Use of rotigotine for treatment or prevention of dopaminergic neuron loss
DE102004014841B4 (de) * 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2007048034A2 (en) * 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of androgens for the treatment of parkinson' s disease
MX2008012683A (es) * 2006-04-06 2009-01-07 Nupathe Inc Implantes para el tratamiento de estados asociados con dopamina.
TW200815045A (en) * 2006-06-29 2008-04-01 Jazz Pharmaceuticals Inc Pharmaceutical compositions of ropinirole and methods of use thereof
WO2008001204A2 (en) * 2006-06-29 2008-01-03 Antares Pharma Ipl Ag Transdermal compositions of pramipexole having enhanced permeation properties
US20090247537A1 (en) * 2008-03-25 2009-10-01 William Dale Overfield Methods for preventing or treating bruxism using dopaminergic agents
CN101574341B (zh) * 2008-05-05 2012-12-19 北京德众万全医药科技有限公司 一种罗匹尼罗的口服固体药物组合物
US20110195117A1 (en) * 2008-09-01 2011-08-11 Lupin Limited Controlled release compositions of ropinirole
US20110262537A1 (en) 2008-09-29 2011-10-27 Premchand Nakhat Extended release dosage form of ropinirole
WO2010044108A2 (en) 2008-10-17 2010-04-22 Rubicon Research Private Limited Controlled release formulations of ropinirole
US20100233259A1 (en) * 2008-12-12 2010-09-16 Pascal Grenier Dosage form of ropinirole
AU2011248904B2 (en) 2010-04-30 2014-02-27 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
JP5913614B2 (ja) 2011-11-09 2016-04-27 テイコク ファーマ ユーエスエー インコーポレーテッド 皮膚新生物の処置方法
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
WO2015168616A1 (en) * 2014-05-02 2015-11-05 Abbvie Inc. Neuronal nicotinic agonists and methods of use

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588740A (en) * 1982-12-07 1986-05-13 Smithkline Beckman Corporation Pharmaceutical methods using 4-aminoalkyl-2(3H)-indolones
US4452808A (en) * 1982-12-07 1984-06-05 Smithkline Beckman Corporation 4-Aminoalkyl-2(3H)-indolones

Also Published As

Publication number Publication date
CA1305421C (en) 1992-07-21
EP0299602A2 (en) 1989-01-18
IE63511B1 (en) 1995-05-03
AU599792B2 (en) 1990-07-26
IE881469L (en) 1988-11-21
NL970006I1 (nl) 1997-04-01
LU90098I2 (fr) 1997-09-25
US4824860A (en) 1989-04-25
ATE83659T1 (de) 1993-01-15
PT87542A (pt) 1989-05-31
NL970006I2 (nl) 1997-10-01
NZ224709A (en) 1997-02-24
HUT47217A (en) 1989-02-28
AU1644588A (en) 1988-11-24
JPS63303966A (ja) 1988-12-12
HK1000913A1 (en) 1998-05-08
DE3876877D1 (de) 1993-02-04
MX9203543A (es) 1992-07-01
ES2052717T3 (es) 1994-07-16
EP0299602A3 (en) 1990-06-06
DK275488D0 (da) 1988-05-19
US4912126A (en) 1990-03-27
DK169609B1 (da) 1994-12-27
GB8712073D0 (en) 1987-06-24
PH23867A (en) 1989-11-23
DK275488A (da) 1988-11-22
EP0299602B1 (en) 1992-12-23
HU201871B (en) 1991-01-28
DE3876877T2 (de) 1993-04-29
ZA883602B (en) 1989-04-26
PT87542B (pt) 1992-09-30
JPH062672B2 (ja) 1994-01-12

Similar Documents

Publication Publication Date Title
GB8712073D0 (en) Medicament
HU913283D0 (en) Process for the production of hydroximethyl-(methylene-cyclopentyl)-purines and pirimidines, their medically usable salts, and of medical preparations containing them
EP0285008A3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
DE3566404D1 (en) Substituted benzopyrans, process for their preparation and their use in medicines
TW231268B (el)
EP0328924A3 (en) Thienotriazolodiazepine compounds and pharmaceutical uses thereof
EP0437929A3 (en) Use of diadenosine-5',5'''-p1,p4-tetraphosphate for the manufacture of a medicament for the treatment of heart disease
GR3025518T3 (en) Use of the N-n-butyl derivative of desoxynojirimycin in the manufacture of a medicament inhibiting HIV-Virus
NZ303993A (en) Pharmaceutical compositions containing aminotetralin derivatives for treating cardiac disorders
GR3000831T3 (en) Piperazine compounds, process for preparing them, pharmaceutical composition and use
GB8608893D0 (en) D-nor-7-ergoline derivatives
HK127294A (en) Use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo [4,5-d] azepin for the preparation of a medicament for the treatment of Parkinson's disease, or of Parkinsonism
GR3037039T3 (en) Use of trimetazidine for the preparation of medicaments for the treatment of troubles due to the therapeutical use of immunosuppressants.
EP0202986A3 (en) Use of "naftidrofuryl" in the treatment of neuropathies
ZA897549B (en) Medicament for the treatment of diseases caused by retroviruses
OA09790A (en) "Paromomycin or its derivatives or salts thereof for parenteral treatment of human parasitic diseases".
Salmaso et al. Serratia spp. bacteremias in AIDS/ARC patients.
CS289389A1 (en) Medicament for stomach's ulcerous disease treatment
JPS6490158A (en) 1,2-diamino compound, manufacture and medicine for treating cardiac disease and circulatory disease
SG114394G (en) Use of 2-amino-6-allyl-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepin for the preparation of a medicament for the treatment of Parkinson's disease or of parkinsonism
EP0207514A3 (en) 1,4-dihydropyridine derivatives, process for preparing them, pharmaceutical composition and use
IL106709A0 (en) Therapeutic uses of 2',5'-oligoadenylates